Targeting FOXO3 for the Management of Heart Failure: Current Evidence and Future Directions

See-Hyoung Park · 2026

Read Targeting FOXO3 for the Management of Heart Failure: Current Evidence and Future Directions by See-Hyoung Park (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13610271.txt.

Description

See-Hyoung Park reviews a longevity-linked protein as a heart failure target in a 2026 paper. The transcription factor FOXO3 steers cell defenses against oxidative stress, cell death, self-digestion, and inflammation. When its control slips, heart failure worsens, which makes it an attractive drug target.

Park surveys FOXO3-modulating compounds studied between 2006 and 2026, from plant chemicals to pharmaceuticals, and the pathways through which they act. In animal and cell models many improved heart function. Yet translation to patients remains the weak point, and the review names the field's method limits plainly. It closes with directions for better experiments, aiming to move FOXO3 from a promising switch to a tested therapy.

Catalog record

CREATORSee-Hyoung Park
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE51 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13610271

Browse the full library · About the Tower of Babel